Herantis Pharma
Herantis Pharma har bevakats av 2 analytiker: Redeye och Carlsquare Equity Research. Här är samtliga 8 artiklar från dem, samlade på en sida.
Analytiker som bevakat bolaget
Bevisnivån visar vad som är belagt om att bolaget betalat för bevakningen, för varje analytiker för sig. Utfallet är kursutvecklingen sedan analytikerns första publicering — analytikerna började vid olika tidpunkter och mäter därför olika perioder.
| Analytiker | Period | Publiceringar | Bevisnivå | Utfall |
|---|---|---|---|---|
| Redeye | 2021-05-18 –2026-04-13 | 7 | Upprepad bevakning | −50,6 % |
| Carlsquare Equity Research | 2022-11-28 | 1 | Angiven som kund | −30,1 % |
Klicka på en analytiker för hela uträkningen: kurs vid start, årsmärken och källor.
Kapitalanskaffning och aktörer
Enligt bolagets egna pressmeddelanden, prospekt och årsredovisningar; varje uppgift har en källa. Regler och begränsningar står på metodsidan.
Sökt efter Redeye AB, Redeye Nordic Growth AB och Redeye Sweden AB i hela texten i alla 857 pressmeddelanden i bolagets arkiv hos MFN, maj 2014–augusti 2026. Ingen roll hittades. Arkivet
Sökt efter Carlsquare AB i hela texten i alla 857 pressmeddelanden i bolagets arkiv hos MFN, maj 2014–augusti 2026. Ingen roll hittades. Arkivet
Alla aktieemissioner och units har sökts i alla 857 pressmeddelanden i bolagets arkiv hos MFN, maj 2014–augusti 2026. 17 emissioner hittades och står nedan. Konvertibler och obligationer ingår inte. Arkivet
Övriga aktörer är inte undersökta.
Emissioner 17
- Period
- 2014–2026
- Tillfört kapital
- 43,9 MSEK1 av 17 emissioner anger beloppet
Datum: 11 februari 2026Typ: Riktad emissionSökt: ej angivetTillfört: ej angivetTeckningskurs: 1,75 EUR−17 % mot kursen 2026-02-10Garanti: ej angivet
- Teckningskurs
- 1,75 EUR per aktie
Riktad emission av 2 409 000 aktier till institutionella och andra kvalificerade investerare; registrerades i två delar (1 837 571 aktier 2026-02-13 och 571 429 aktier 2026-03-02).
Ej angivet i källan: sökt, tillfört, varav kvittning, emissionskostnad, garanti. Inte undersökt: finansiell rådgivare, emissionsinstitut.
Källor och citat (3 källor)
- Datum
2026-02-11 22:45:00
Inside information: Herantis Pharma Plc successfully completes a directed share issue raising EUR 4.2 million 2026-02-11 - Typ
Herantis Pharma Plc ("Herantis" or the "Company"), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, has carried out an offering of new shares (the "New Shares") in a directed share issue to institutional and other qualified investors (the "Directed Issue").
Inside information: Herantis Pharma Plc successfully completes a directed share issue raising EUR 4.2 million 2026-02-11 - Teckningskurs
The subscription price is EUR 1.75 per New Share
Inside information: Herantis Pharma Plc successfully completes a directed share issue raising EUR 4.2 million 2026-02-11 - Upplägg
In the Directed Issue, the Company issued a total of 2,409,000 new shares, of which 1,837,571 new shares have today been registered with the trade register maintained by the Finnish Patent and Registration Office (the "New Shares").
Herantis Pharma Plc: 1,837,571 new shares registered with the trade register 2026-02-13 - Upplägg
In the Directed Issue, the Company issued a total of 2,409,000 new shares, of which the remaining 571,429 have today been registered with the trade register maintained by the Finnish Patent and Registration Office (the "New Shares").
Herantis Pharma Plc: 571,429 new shares registered with the trade register 2026-03-02
Datum: 6 februari 2025Typ: Riktad emissionSökt: ej angivetTillfört: ej angivetTeckningskurs: 1,32 EUR−11 % mot kursen 2025-02-05Garanti: ej angivet
- Teckningskurs
- 1,32 EUR per aktie
Riktad emission av 3 934 084 aktier till institutionella och andra kvalificerade investerare; registrerades i två delar (2 622 721 aktier 2025-02-10 och 1 311 363 aktier 2025-02-17).
Ej angivet i källan: sökt, tillfört, varav kvittning, emissionskostnad, garanti. Inte undersökt: finansiell rådgivare, emissionsinstitut.
Källor och citat (3 källor)
- Datum
2025-02-06 19:30:00
Inside information: Herantis Pharma Plc successfully completes a directed share issue raising EUR 5.2 million 2025-02-06 - Typ
Herantis Pharma Plc Company release, inside information, 6 February 2025 at 20:30 (EET) Inside information: Herantis Pharma Plc successfully completes a directed share issue raising EUR 5.2 million Herantis Pharma Plc ("Herantis" or the "Company"), a company developing disease-modifying therapies for Parkinson's disease, has carried out an offering of new shares (the "New Shares") in a directed share issue to institutional and other qualified investors (the "Directed Issue").
Inside information: Herantis Pharma Plc successfully completes a directed share issue raising EUR 5.2 million 2025-02-06 - Teckningskurs
The subscription price is EUR 1.32 per New Share
Inside information: Herantis Pharma Plc successfully completes a directed share issue raising EUR 5.2 million 2025-02-06 - Upplägg
In the Directed Issue, the Company issued a total of 3,934,084 new shares, of which 2,622,721 new shares have today been registered with the trade register maintained by the Finnish Patent and Registration Office (the "New Shares").
Herantis Pharma Plc: 2,622,721 new shares registered with the trade register 2025-02-10 - Upplägg
In the Directed Issue, the Company issued a total of 3,934,084 new shares, of which the remaining 1,311,363 new shares have today been registered with the trade register maintained by the Finnish Patent and Registration Office (the "New Shares").
Herantis Pharma Plc: 1,311,363 new shares registered with the trade register 2025-02-17
Datum: 5 december 2023Typ: Riktad emissionSökt: ej angivetTillfört: ej angivetTeckningskurs: 1,4 EUR−22 % mot kursen 2023-12-04Garanti: ej angivet
- Teckningskurs
- 1,4 EUR per aktie
Riktad emission av 3 219 139 aktier till institutionella och andra kvalificerade investerare; registrerades i två delar (2 147 710 aktier 2023-12-08 och 1 071 429 aktier 2023-12-13).
Ej angivet i källan: sökt, tillfört, varav kvittning, emissionskostnad, garanti. Inte undersökt: finansiell rådgivare, emissionsinstitut.
Källor och citat (3 källor)
- Datum
2023-12-05 19:45:00
Inside information: Herantis Pharma Plc successfully completes a directed share issue raising EUR 4.51 million 2023-12-05 - Typ
EET Herantis Pharma Plc ("Herantis" or the "Company"), a clinical-stage biotechnology company developing disease modifying therapies for Parkinson's disease, has carried out an offering of new shares (the "New Shares") in a directed share issue to institutional and other qualified investors (the "Directed Issue").
Inside information: Herantis Pharma Plc successfully completes a directed share issue raising EUR 4.51 million 2023-12-05 - Teckningskurs
The subscription price is EUR 1.40 per New Share
Inside information: Herantis Pharma Plc successfully completes a directed share issue raising EUR 4.51 million 2023-12-05 - Upplägg
In the Directed Issue, the Company issued a total of 3,219,139 new shares, of which 2,147,710 new shares have today been registered with the trade register maintained by the Finnish Patent and Registration Office (the "New Shares").
Herantis Pharma Plc: 2,147,710 new shares registered with the trade register 2023-12-08 - Upplägg
In the Directed Issue, the Company issued a total of 3,219,139 new shares, of which the remaining 1,071,429 new shares have today been registered with the trade register maintained by the Finnish Patent and Registration Office (the "New Shares").
Herantis Pharma Plc: 1,071,429 new shares registered with the trade register 2023-12-13
Datum: 1 juni 2022Typ: FöreträdesemissionSökt: ej angivetTillfört: ej angivetTeckningskurs: 15,6 SEKGaranti: ej angivet
- Teckningskurs
- 15,6 SEK per aktie
Företrädesemission av 4 831 426 aktier (fem teckningsrätter gav två aktier), fulltecknad. Teckningsåtaganden om upp till 4,1 miljoner euro från befintliga aktieägare lämnades i förväg; de är inte garanti. Aktierna registrerades 2022-06-02.
Ej angivet i källan: sökt, tillfört, varav kvittning, emissionskostnad, garanti. Inte undersökt: finansiell rådgivare, emissionsinstitut.
Källor och citat (3 källor)
- Datum
2022-06-01 19:00:00
Final results of Herantis Pharma Plc's fully subscribed rights issue 2022-06-01 - Typ
Based on the authorization of the Annual General Meeting of Herantis held on 21 April 2022, the Board of Directors of Herantis has today on 3 May 2022 decided to offer Herantis' shareholders up to 4,831,426 new shares (the "Offer Shares") in a rights issue on the basis of shareholders' pre-emptive subscription rights in the same proportion as they already hold shares (the "Existing Shares") in the Company and secondarily by other shareholders or by other persons (the "Offering").
Herantis Pharma Plc's Board of Directors resolved on a rights issue and publishes the terms and conditions of the rights issue 2022-05-03 - Teckningskurs
The subscription price in the Offering was EUR 1.50 per Offer Share in Finland and SEK 15.60 per Offer Share in Sweden
Final results of Herantis Pharma Plc's fully subscribed rights issue 2022-06-01 - Upplägg
The final results of the Offering show that the Offering was subscribed in full.
Final results of Herantis Pharma Plc's fully subscribed rights issue 2022-06-01 - Upplägg
The Company has received commitments for an aggregate amount of up to EUR 4.1 million from its certain existing shareholders to subscribe for Offer Shares in the rights issue with all of the Subscription Rights granted, i.e. pro rata to their shareholding, subject to certain conditions (the "Subscription Commitments").
Herantis Pharma Plc's Board of Directors resolved on a rights issue and publishes the terms and conditions of the rights issue 2022-05-03 - Upplägg
A total of 4,831,426 offer shares (the "Offer Shares") subscribed for in the Offering have been registered with the trade register maintained by the Finnish Patent and Registration Office today on 2 June 2022.
New shares in Herantis Pharma Plc registered with the trade register 2022-06-02
Datum: 30 mars 2022Typ: Riktad emissionSökt: ej angivetTillfört: ej angivetTeckningskurs: 1,5 EUR−25 % mot kursen 2022-03-29Garanti: ej angivet
- Teckningskurs
- 1,5 EUR per aktie
Riktad emission av 975 000 aktier till institutionella och andra kvalificerade investerare, den första av två emissioner 2022 (den andra är företrädesemissionen företrädesemission i juni 2022). Aktierna registrerades 2022-04-04.
Ej angivet i källan: sökt, tillfört, varav kvittning, emissionskostnad, garanti. Inte undersökt: finansiell rådgivare, emissionsinstitut.
Källor och citat (2 källor)
- Datum
2022-03-30 15:00:00
Herantis Pharma Plc successfully completes a directed share issue raising EUR 1.46 million 2022-03-30 - Typ
Herantis Pharma Plc ("Herantis" or the "Company"), an innovative biotech company developing new disease modifying therapies for Parkinson's disease, has carried out an offering of new shares (the "Placing Shares") in a directed share issue to institutional and other qualified investors (the "Directed Issue").
Herantis Pharma Plc successfully completes a directed share issue raising EUR 1.46 million 2022-03-30 - Teckningskurs
The subscription price of the Placing Shares is EUR 1.50 per Placing Share
Herantis Pharma Plc successfully completes a directed share issue raising EUR 1.46 million 2022-03-30 - Upplägg
In the Directed Issue, the Company issued a total of 975,000 Placing Shares.
Herantis Pharma Plc: 975,000 new shares registered with the trade register 2022-04-04 - Upplägg
The Directed Issue was based on the authorization given to the board of directors by the Company’s annual general meeting of 15 April 2021.
Herantis Pharma Plc successfully completes a directed share issue raising EUR 1.46 million 2022-03-30
Datum: 15 september 2021Typ: Riktad emissionSökt: ej angivetTillfört: ej angivetTeckningskurs: 3 EUR−6 % mot kursen 2021-09-14Garanti: ej angivet
- Teckningskurs
- 3 EUR per aktie
Riktad emission av 1 346 500 aktier till institutionella och andra kvalificerade investerare efter accelererad book building. Aktierna registrerades 2021-09-16.
Ej angivet i källan: sökt, tillfört, varav kvittning, emissionskostnad, garanti. Inte undersökt: finansiell rådgivare, emissionsinstitut.
Källor och citat (2 källor)
- Datum
2021-09-15 22:50:00
Herantis Pharma Plc successfully completes private placement raising EUR 4.04 million 2021-09-15 - Typ
In the Placing, the Company expects to issue a total of 1,346,500 Placing Shares in a directed share issue.
Herantis Pharma Plc successfully completes private placement raising EUR 4.04 million 2021-09-15 - Teckningskurs
The subscription price of the Placing Shares is EUR 3.00 per Placing Share
Herantis Pharma Plc successfully completes private placement raising EUR 4.04 million 2021-09-15 - Upplägg
The Placing Shares have today been registered with the trade register maintained by the Finnish Patent and Registration Office.
Herantis Pharma Plc: 1,346,500 new shares registered with the trade register 2021-09-16 - Upplägg
The Placing was carried out based on offers received in an accelerated book building and based on the authorisation given to the board of directors by the Company's extraordinary general meeting of 2 December 2020.
Herantis Pharma Plc successfully completes private placement raising EUR 4.04 million 2021-09-15
Datum: 17 december 2020Typ: Riktad emissionSökt: ej angivetTillfört: ej angivetTeckningskurs: 3,7 EUR−6 % mot kursen 2020-12-16Garanti: ej angivet
- Teckningskurs
- 3,7 EUR per aktie
Riktad emission av 2 162 163 aktier till institutionella och andra kvalificerade investerare efter accelererad book building; ökad från planerade minst 6,5 miljoner euro. Aktierna registrerades 2020-12-18.
Ej angivet i källan: sökt, tillfört, varav kvittning, emissionskostnad, garanti. Inte undersökt: finansiell rådgivare, emissionsinstitut.
Källor och citat (2 källor)
- Datum
announced on 17 December 2020 the result of the offering of new shares
Herantis Pharma Plc: 2,162,163 new shares registered with the trade register 2020-12-18 - Typ
In the Placing, the Company expects to issue a total of 2,162,163 Placing Shares in a directed share issue.
Herantis Pharma Plc successfully completes private placement raising EUR 8 million 2020-12-17 - Teckningskurs
The subscription price of the Placing Shares is EUR 3.70 per Placing Share
Herantis Pharma Plc successfully completes private placement raising EUR 8 million 2020-12-17 - Upplägg
The Placing Shares have today been registered with the trade register maintained by the Finnish Patent and Registration Office.
Herantis Pharma Plc: 2,162,163 new shares registered with the trade register 2020-12-18 - Upplägg
The Placing was carried out based on offers received in an accelerated bookbuilding and based on the authorisations given to the board of directors by the Company's annual general meeting of 8 April 2020 and the extraordinary general meeting of 2 December 2020.
Herantis Pharma Plc successfully completes private placement raising EUR 8 million 2020-12-17
Datum: 27 maj 2020Typ: Riktad emissionSökt: ej angivetTillfört: ej angivetTeckningskurs: 7,8 EUR−3 % mot kursen 2020-05-26Garanti: ej angivet
- Teckningskurs
- 7,8 EUR per aktie
Riktad emission av 875 000 aktier till ett urval investerare efter accelererad book building; ökad från planerade minst 5 miljoner euro. Aktierna registrerades 2020-05-27.
Ej angivet i källan: sökt, tillfört, varav kvittning, emissionskostnad, garanti. Inte undersökt: finansiell rådgivare, emissionsinstitut.
Källor och citat (2 källor)
- Datum
2020-05-27 08:00:00
Herantis Pharma Plc to raise EUR 6.8 million as a result of the directed offering 2020-05-27 - Typ
In the Placing, the Company issues a total of 875,000 Placing Shares in a directed share issue, provided that the Placing Shares subscribed in the Placing are paid according to the terms and conditions of the Placing.
Herantis Pharma Plc to raise EUR 6.8 million as a result of the directed offering 2020-05-27 - Teckningskurs
The subscription price of the Placing Shares is EUR 7.80 per Placing Share
Herantis Pharma Plc to raise EUR 6.8 million as a result of the directed offering 2020-05-27 - Upplägg
The Placing Shares have today been registered with the trade register maintained by the Finnish Patent and Registration Office.
New shares in Herantis Pharma Plc registered with the trade register 2020-05-27 - Upplägg
The Placing was carried out based on offers received in an accelerated bookbuilding and based on the authorisation given by the Company's annual general meeting to the board of directors on 8 April 2020.
Herantis Pharma Plc to raise EUR 6.8 million as a result of the directed offering 2020-05-27
Datum: 2 december 2019Typ: Riktad emissionSökt: ej angivetTillfört: 43,9Teckningskurs: 71 SEKGaranti: ej angivet
- Tillfört
- 43,9 MSEK
- Teckningskurs
- 71 SEK per aktie
Emission av 618 018 aktier: offentligt erbjudande i Sverige och Danmark (360 000 aktier) och riktad nyemission till kvalificerade investerare (258 018 aktier, varav utökningsoptionen). Bolaget kallar den "directed share issue"; erbjudandet gjordes inför en sekundärnotering på First North Sverige. Aktierna registrerades 2019-12-09.
Ej angivet i källan: sökt, varav kvittning, emissionskostnad, garanti. Inte undersökt: finansiell rådgivare, emissionsinstitut.
Källor och citat (2 källor)
- Datum
2019-12-02 19:00:00
Herantis Pharma Plc's directed share issue is oversubscribed multiple times and completed as planned 2019-12-02 - Typ
In the Offering, the Company issues a total of 618,018 new shares (the "Offer Shares") in a directed share issue (the "Offering"), provided that the Offer Shares subscribed in the Offering are paid according to the terms and conditions of the Offering.
Herantis Pharma Plc's directed share issue is oversubscribed multiple times and completed as planned 2019-12-02 - Tillfört
The Company raises gross proceeds of approximately SEK 43.9 million in the Offering.
Herantis Pharma Plc's directed share issue is oversubscribed multiple times and completed as planned 2019-12-02 - Teckningskurs
The subscription price for each Offer Share was SEK 71 per Offer Share
Herantis Pharma Plc's directed share issue is oversubscribed multiple times and completed as planned 2019-12-02 - Upplägg
As the Offering was oversubscribed multiple times, the board of directors of the Company resolved to use the upsize option in the Private Placement (as defined below) according to the terms and conditions of the Offering by increasing the number of the Offer Shares in the Private Placement by 258,018 Offer Shares.
Herantis Pharma Plc's directed share issue is oversubscribed multiple times and completed as planned 2019-12-02 - Upplägg
A total of 618,018 Offer Shares subscribed for in the Offering have been registered in the trade register maintained by the Finnish Patent and Registration Office today on 9 December 2019.
Offer shares of Herantis Pharma Plc registered with the Trade Register 2019-12-09
Datum: 28 maj 2019Typ: Inlösen av teckningsoptionerSökt: ej angivetTillfört: ej angivetTeckningskurs: ej angivetGaranti: ej angivet
Utnyttjande av optionsrätter (optionsprogram 2010 och 2014); hela teckningsbeloppet bokförs i fonden för fritt eget kapital och aktiekapitalet ökar inte.
Ej angivet i källan: sökt, tillfört, varav kvittning, teckningskurs, emissionskostnad, garanti. Inte undersökt: finansiell rådgivare, emissionsinstitut.
Källor och citat (1 källa)
- Datum
2019-05-28 08:00:00
Herantis Pharma Plc shares subscribed with option rights 2019-05-28 - Typ
32,000 new shares of Herantis Pharma Plc have been subscribed with option rights
Herantis Pharma Plc shares subscribed with option rights 2019-05-28 - Upplägg
The share capital will not increase with subscriptions.
Herantis Pharma Plc shares subscribed with option rights 2019-05-28
Datum: 12 mars 2019Typ: Riktad emissionSökt: ej angivetTillfört: ej angivetTeckningskurs: 5,2 EUR−2 % mot kursen 2019-03-11Garanti: ej angivet
- Teckningskurs
- 5,2 EUR per aktie
Riktad emission av 1 111 982 aktier till institutionella investerare, andra investerare och bolagets styrelseledamöter, med stöd av extra bolagsstämmans bemyndigande 2019-03-12. Aktierna registrerades 2019-03-22.
Ej angivet i källan: sökt, tillfört, varav kvittning, emissionskostnad, garanti. Inte undersökt: finansiell rådgivare, emissionsinstitut.
Källor och citat (2 källor)
- Datum
2019-03-12 16:00:00
Herantis Pharma Plc Announces Positive Outcome of Directed Share Issue Raising EUR 5.8 Million 2019-03-12 - Typ
has today decided on a directed share issue of 1.111.982 new shares in aggregate, at a per-share subscription price of EUR 5.20
Herantis Pharma Plc Announces Positive Outcome of Directed Share Issue Raising EUR 5.8 Million 2019-03-12 - Teckningskurs
at a per-share subscription price of EUR 5.20
Herantis Pharma Plc Announces Positive Outcome of Directed Share Issue Raising EUR 5.8 Million 2019-03-12 - Upplägg
The Issue Shares have today been registered with the trade register maintained by the Finnish Patent and Registration Office.
Herantis Pharma Plc: Change in the number of shares and voting rights 2019-03-22 - Upplägg
The share issue was based on an authorization of the Company’s Extraordinary Meeting of Shareholders convening on 12 March 2019.
Herantis Pharma Plc Announces Positive Outcome of Directed Share Issue Raising EUR 5.8 Million 2019-03-12
Datum: 9 november 2017Typ: Riktad emissionSökt: ej angivetTillfört: ej angivetTeckningskurs: 5,85 EUR−1 % mot kursen 2017-11-08Garanti: ej angivet
- Teckningskurs
- 5,85 EUR per aktie
Riktad emission av 800 000 aktier till institutionella investerare, kvalificerade investerare och bolagets styrelseledamöter, beslutad av styrelsen efter extra bolagsstämma 2017-11-09. Teckningsåtaganden om 778 000 aktier lämnades i förväg (de är inte garanti). Något registreringsmeddelande finns inte i arkivet.
Ej angivet i källan: sökt, tillfört, varav kvittning, emissionskostnad, garanti. Inte undersökt: finansiell rådgivare, emissionsinstitut.
Källor och citat (2 källor)
- Datum
2017-11-09 18:00:00
Herantis Pharma Plc's directed share issue 2017-11-09 - Typ
has today decided on a directed share issue of 800,000 new shares in aggregate
Herantis Pharma Plc's directed share issue 2017-11-09 - Teckningskurs
at a per-share subscription price of EUR 5.85
Herantis Pharma Plc's directed share issue 2017-11-09 - Upplägg
The share issue was based on an authorization of the Company's Extraordinary Meeting of Shareholders convening on 9 November 2017.
Herantis Pharma Plc's directed share issue 2017-11-09 - Upplägg
Herantis has received subscription undertakings from certain institutional investors and a limited number of qualified investors as well as certain directors of the Company, under which said parties have committed to subscribe, subject to certain conditions being fulfilled, for a total of 778,000 shares at a subscription price of 5.85 euros per share in the possible share issue.
Herantis Pharma Plc is planning a directed share issue to a limited number of investors and the company's directors regarding the financing of the Lymfactin Phase 2 clinical study 2017-10-19
Datum: 14 januari 2016Typ: Riktad emissionSökt: ej angivetTillfört: ej angivetTeckningskurs: 10 EURGaranti: ej angivet
- Teckningskurs
- 10 EUR per aktie
Riktad emission av 32 311 aktier till en enda investerare; aktierna registrerades 2016-01-12 och meddelandet publicerades 2016-01-14.
Ej angivet i källan: sökt, tillfört, varav kvittning, emissionskostnad, garanti. Inte undersökt: finansiell rådgivare, emissionsinstitut.
Källor och citat (1 källa)
- Datum
2016-01-14 09:00:00
Herantis Pharma Plc's directed share issue and share subscription by Broadview Ventures I, LLC 2016-01-14 - Typ
The Board of Directors of Herantis Pharma Plc has decided on a directed share issue
Herantis Pharma Plc's directed share issue and share subscription by Broadview Ventures I, LLC 2016-01-14 - Teckningskurs
for a subscription price of EUR 10.00 per share
Herantis Pharma Plc's directed share issue and share subscription by Broadview Ventures I, LLC 2016-01-14 - Upplägg
Broadview Ventures I, LLC has fully subscribed to this share issue, total of 32,311 new shares in Herantis Pharma Plc for a subscription price of EUR 10.00 per share.
Herantis Pharma Plc's directed share issue and share subscription by Broadview Ventures I, LLC 2016-01-14 - Upplägg
The new shares have been registered in the Trade Register on 12 January 2016, as of which date the new shares will establish shareholder rights.
Herantis Pharma Plc's directed share issue and share subscription by Broadview Ventures I, LLC 2016-01-14
Datum: 25 september 2015Typ: Inlösen av teckningsoptionerSökt: ej angivetTillfört: ej angivetTeckningskurs: ej angivetGaranti: ej angivet
Utnyttjande av optionsrätter (optionsprogram 2010 och 2014); hela teckningsbeloppet bokförs i fonden för fritt eget kapital och aktiekapitalet ökar inte.
Ej angivet i källan: sökt, tillfört, varav kvittning, teckningskurs, emissionskostnad, garanti. Inte undersökt: finansiell rådgivare, emissionsinstitut.
Källor och citat (1 källa)
- Datum
2015-09-25 08:00:00
Herantis Pharma plc shares subscribed with option rights 2015-09-25 - Typ
18,200 new shares of Herantis Pharma plc. have been subscribed with option rights
Herantis Pharma plc shares subscribed with option rights 2015-09-25 - Upplägg
The share capital will not increase with subscriptions.
Herantis Pharma plc shares subscribed with option rights 2015-09-25
Datum: 1 juni 2015Typ: Inlösen av teckningsoptionerSökt: ej angivetTillfört: ej angivetTeckningskurs: ej angivetGaranti: ej angivet
Utnyttjande av optionsrätter (optionsprogram 2010 och 2014); hela teckningsbeloppet bokförs i fonden för fritt eget kapital och aktiekapitalet ökar inte.
Ej angivet i källan: sökt, tillfört, varav kvittning, teckningskurs, emissionskostnad, garanti. Inte undersökt: finansiell rådgivare, emissionsinstitut.
Källor och citat (1 källa)
- Datum
2015-06-01 08:00:00
Herantis Pharma plc shares subscribed with option rights 2015-06-01 - Typ
5,580 new shares of Herantis Pharma plc. have been subscribed with option rights
Herantis Pharma plc shares subscribed with option rights 2015-06-01 - Upplägg
The share capital will not increase with subscriptions.
Herantis Pharma plc shares subscribed with option rights 2015-06-01
Datum: 10 november 2014Typ: Inlösen av teckningsoptionerSökt: ej angivetTillfört: ej angivetTeckningskurs: ej angivetGaranti: ej angivet
Utnyttjande av optionsrätter (optionsprogram 2010); hela teckningsbeloppet bokförs i fonden för fritt eget kapital och aktiekapitalet ökar inte.
Ej angivet i källan: sökt, tillfört, varav kvittning, teckningskurs, emissionskostnad, garanti. Inte undersökt: finansiell rådgivare, emissionsinstitut.
Källor och citat (1 källa)
- Datum
2014-11-10 10:00:00
Herantis Pharma plc shares subscribed with option rights 2014-11-10 - Typ
4000 new shares of Herantis Pharma plc. have been subscribed with option rights
Herantis Pharma plc shares subscribed with option rights 2014-11-10 - Upplägg
The share capital will not increase with subscriptions.
Herantis Pharma plc shares subscribed with option rights 2014-11-10
Datum: 4 juni 2014Typ: Nyemission vid noteringSökt: ej angivetTillfört: ej angivetTeckningskurs: 10,5 EURGaranti: ej angivet
- Teckningskurs
- 10,5 EUR per aktie
Nyemission (riktad emission med offentligt erbjudande) i samband med noteringen på First North Finland; av högst 1 600 000 aktier betalades 1 364 770 enligt villkoren (1 384 070 tecknades). Aktierna registrerades 2014-06-06 och handeln började 2014-06-11. Datum är det slutliga utfallet 2014-06-04.
Ej angivet i källan: sökt, tillfört, varav kvittning, emissionskostnad, garanti. Inte undersökt: finansiell rådgivare, emissionsinstitut.
Källor och citat (3 källor)
- Datum
2014-06-04 15:01:22
Final results of the initial public offering of Herantis Pharma 2014-06-04 - Typ
is launching its initial public offering and will apply for listing of its shares on First North Finland
Herantis Pharma launches its initial public offering and applies for listing on First North 2014-05-12 - Teckningskurs
The subscription price was EUR 10.50 per share
Final results of the initial public offering of Herantis Pharma 2014-06-04 - Upplägg
In the share issue, in total 1,364,770 shares were subscribed and paid for in accordance with the share issue terms and conditions.
Final results of the initial public offering of Herantis Pharma 2014-06-04 - Upplägg
The shares issued in the share issue were registered with the Trade Register on 6 June 2014.
Trading in the shares of Herantis Pharma to commence today 2014-06-11
"Ej angivet" betyder att källan är läst och inte säger det. "Inte undersökt" betyder att ingen har letat än. Garanter namnges bara när de är värdepappersbolag med tillstånd från Finansinspektionen eller hör till ett analyshus eller dess koncern.
Kurs och publiceringar över tid
- Publicerad analys
- Bevakningens start, en per analytiker
- Emission, med teckningskursen som ett streck
| Datum | Typ | Teckningskurs | Mot stängningskursen före |
|---|---|---|---|
| 2014-06-04 | Nyemission vid notering | ingen att jämföra mot kurvan | — |
| 2014-11-10 | Inlösen av teckningsoptioner | ingen att jämföra mot kurvan | — |
| 2015-06-01 | Inlösen av teckningsoptioner | ingen att jämföra mot kurvan | — |
| 2015-09-25 | Inlösen av teckningsoptioner | ingen att jämföra mot kurvan | — |
| 2016-01-14 | Riktad emission | ingen att jämföra mot kurvan | — |
| 2017-11-09 | Riktad emission | 5,8500 EUR | −1,1 % |
| 2019-03-12 | Riktad emission | 5,2000 EUR | −2,4 % |
| 2019-05-28 | Inlösen av teckningsoptioner | ingen att jämföra mot kurvan | — |
| 2019-12-02 | Riktad emission | ingen att jämföra mot kurvan | — |
| 2020-05-27 | Riktad emission | 7,8000 EUR | −2,6 % |
| 2020-12-17 | Riktad emission | 3,7000 EUR | −6,5 % |
| 2021-09-15 | Riktad emission | 3,0000 EUR | −6,1 % |
| 2022-03-30 | Riktad emission | 1,5000 EUR | −24,9 % |
| 2022-06-01 | Företrädesemission | ingen att jämföra mot kurvan | — |
| 2023-12-05 | Riktad emission | 1,4000 EUR | −22,2 % |
| 2025-02-06 | Riktad emission | 1,3200 EUR | −10,8 % |
| 2026-02-11 | Riktad emission | 1,7500 EUR | −16,7 % |
Alla publiceringar
Den senaste först. Varje rubrik länkar till originalet hos analytikern.
- 2026-04-13 Redeye Herantis Pharma: CEO Antti Vuolanto is interviewed by Redeye’s analyst
- 2024-03-11 Redeye Herantis H2 2023 - Presented positive phase I data
- 2023-10-26 Redeye Herantis Pharma - Positive phase Ia data
- 2023-08-25 Redeye Herantis H1 2023 - Progress in the clinic
- 2023-03-03 Redeye Herantis H2 2022 - Important progress
- 2023-01-09 Redeye Herantis Pharma - Soon again a (stronger) clinical company
- 2022-11-28 Carlsquare Equity Research Herantis Pharma at Carlsquare Nordic life science investor day
- 2021-05-18 Redeye Redeye Initiates Coverage of Herantis Pharma